ASH 2018

ASH 2018

The 2018 American Society of Hematology annual meeting will be held in San Diego, California.

Fred Hutch scientists are presenting new research findings at the American Society of Hematology (ASH) Annual Meeting, the world's most comprehensive hematology event, on December 1-4, 2018. 

The meeting features the E. Donnall Thomas Lecture and Prize, created in 1992 and named after the late Nobel laureate who pioneered bone marrow transplantation at Fred Hutch and served as a past ASH president. The lecture and prize recognizes pioneering research achievements in hematology that have represented a paradigm shift or significant discovery in the field.

Fred Hutch researchers are presenting 50 talks and posters on a number of topics including cellular immunotherapies for leukemia, lymphoma and myeloma; gene therapy for hemoglobinopathies; hematopoietic cell transplantation; immune regeneration; and precision medicine for blood cancers.

A talk by the Hutch’s Dr. Jordan Gauthier on CAR T-cell combination therapy for leukemia will be featured in the ASH press program. The briefing, “CAR T-Cell Therapies: New Research and Updates from Pivotal Trials,” will take place at 11:30 a.m. PST, Saturday, Dec 1, in Room 23 of the San Diego Convention Center. 

More information about Fred Hutch science at ASH is available in our media tip sheet.

 

LBA-1 Rivaroxaban Thromboprophylaxis in High-Risk Ambulatory Cancer Patients Receiving Systemic Therapy: Results of a Randomized Clinical Trial (CASSINI)

Alok A. Khorana, MD
Tuesday, December 4, 2018, 7:30 AM
Hall AB (San Diego Convention Center)

Patients on systemic therapy for cancer are at varying risk for venous thromboembolism (VTE) and its consequences. Thromboprophylaxis is recommended in hospitalized medical and surgical cancer patients, but most VTE occurs in ambulatory cancer patients where risk can be estimated with a validated score. However, the benefit of extended outpatient thromboprophylaxis is uncertain with heparins and has not been tested with direct oral anticoagulants. Read more.


702 Clonal Kinetics and Single Cell Transcriptional Profiling of Adoptively Transferred CD19 CAR-T Cells

Alyssa Sheih, PhD
Monday, December 3, 2018, 11:45 AM
San Diego Ballroom B (Marriott Marquis San Diego Marina)

When introduced into polyclonal T cells, chimeric antigen receptors (CAR) redirect specificity of the engineered T cells to an antigen recognized by the CAR. We conducted a phase I/II clinical trial of treatment of relapsed and refractory CD19-positive B cell malignancies using a defined formulation of CD4+ and CD8+ CD19-specific CAR-T cells (NCT01865617). Little is known about the transcriptional heterogeneity of CAR-T cells in the infused product and their clonal kinetics after adoptive transfer. Read more.


1011 Fully Human Bcma Targeted Chimeric Antigen Receptor T Cells Administered in a Defined Composition Demonstrate Potency at Low Doses in Advanced Stage High Risk Multiple Myeloma

Damian J. Green, MD
Monday, December 3, 2018: 6:45 PM
Ballroom 20D (San Diego Convention Center)

Despite advances in the treatment of multiple myeloma (MM) almost all patients relapse and high risk features continue to portend a short median survival. The adoptive transfer of B-Cell Maturation Antigen (BCMA) chimeric antigen receptor (CAR) T cells is demonstrating early promise in MM, but the durability of response has not been established. The infusion of genetically modified CD8+ and CD4+ T cells of a defined composition facilitates the evaluation of each subset’s function and has contributed to reproducible efficacy and safety in clinical trials with CD19-specific CAR T cells. In this phase I first-in-human study employing a human scFv containing BCMA CAR T cell construct, we report rapid and deep objective responses at a low CAR T cell dose level (5 x 107) suggesting that construct specific features and differences in product formulation may substantially impact efficacy. Read more.


281 Multivariable Modeling of Disease and Treatment Characteristics of Adults with B-ALL in MRD-Negative CR after CD19 CAR-T Cells Identifies Factors Impacting Disease-Free Survival

Kevin A. Hay, MD, MSc
Sunday, December 2, 2018, 8:30 AM
Ballroom 20D (San Diego Convention Center)

Autologous T cells expressing a CD19-specific chimeric antigen receptor (CAR) have produced impressive minimal residual disease-negative complete remission (MRD-neg CR) rates in relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) patients (pts). Factors associated with durable remission in pts achieving MRD-neg CR after immunotherapy with T cells engineered with a CD19 CAR (FMC63.41bb.3ζ) have not been elucidated. Read more.


94 Outcomes of Patients with Large B-Cell Lymphomas and Progressive Disease Following CD19-Specific CAR T-Cell Therapy

Victor A. Chow, MD
Saturday, December 1, 2018: 10:15 AM
Pacific Ballroom 20 (Marriott Marquis San Diego Marina)

CD19-specific chimeric antigen receptor (CAR) T-cell therapy has proven to be highly effective in patients with relapsed or refractory large B-cell lymphomas, yielding early complete response (CR) rates of ~40%, which are typically sustained. Unfortunately, most patients will not experience prolonged disease control. Despite this fact, little data exist defining the outcomes and impact of subsequent therapies for such individuals. Limited data also exist on the ability for such patients to pursue further clinical trials or allogeneic hematopoietic stem-cell transplant (HSCT). This project details the specific interventions and outcomes of this population to better inform the management of patients who suffer progressive disease (PD) after CD19-specific CAR T-cell therapy. Read more


806 Persistence of CRISPR/Cas9-Edited Hematopoietic Stem and Progenitor Cells and Reactivation of Fetal Hemoglobin in Nonhuman Primates

Stefan Radtke, PhD
Monday, December 3, 2018: 3:00 PM
Grand Hall C (Manchester Grand Hyatt San Diego)

Beta-thalassemia and sickle cell disease are monogenic disorders that are currently treated by allogeneic bone marrow (BM) transplantation although the challenges of finding a suitable matched-donor and the risk of graft vs host disease have limited the adoption of this otherwise curative treatment. A potentially promising approach for hemoglobinopathies aims to reactivate fetal hemoglobin (HbF) as a substitute for defective or absent adult hemoglobin by modifying the patient’s own hematopoietic stem and progenitor cells (HSPCs). Here, we evaluated CRISPR/Cas9-induced small deletions in HSPCs that are associated with hereditary persistence of fetal hemoglobin (HPFH) using our nonhuman primate (NHP) stem cell transplantation and gene therapy model. Read more


207 Survival Differences Among Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Non-HCT Therapies: A Large Real-Time Multi-Center Prospective Longitudinal Observational Study

Mohamed L. Sorror, MD, MSc
Saturday, December 1, 2018: 2:30 PM
Seaport Ballroom A (Manchester Grand Hyatt San Diego)

Survival rates continue to improve after allogeneic HCT (Gooley et al, NEJM, 2013). Population-based studies also indicate overall improvement in survival of older (60-80 years old) AML patients (pts) (Bower, Blood Cancer Journal, 2016). Yet, only a small minority (6%-8%) of them receive HCT (Medeiros, Ann Hematol. 2015). Given these potentially incongruent findings and the changing face of survival in AML, we designed the first prospective multi-center longitudinal study dating from first presentation of adults with AML to be treated at one of 13 different referral centers that provide both AML treatment and HCT. We compared survival according to whether or not pts received HCT at later time points. Read more

Stories from ASH

FOR THE MEDIA

Hutch Team

For more information or to arrange an interview, please contact Molly McElroy at 206.667.6651 or email our media relations team.

file

ACCESS INFORMATION OR DOWNLOAD HIGH-RES PHOTOS AND VIDEO

Media Coverage